EU Marketing Authorization Rejected for Bone Disorder Drug EU Marketing Authorization Rejected for Bone Disorder Drug
French drugmaker Ipsen said on Wednesday the European Commission has not granted marketing authorization for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Diabetes | Endocrinology | Fibrodysplasia Ossificans Progressiva | France Health | Health | Marketing